ERT

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Bone marrow, Mutation, Cell, Risk, Blood, News, Research, ERT, White blood cell, Glycogen storage disease, SRT, ALT, GBA1, White, European Medicines Agency, Brain, Enzyme replacement therapy, Regenerative Medicine Advanced Therapy, Therapy, Plasma, Patient, Mouse, Safety, Tissue, Glucocerebrosidase, Substantia nigra, Lysosome, Neuropsychological test, AAV, Dementia, PRIME, Fatigue, EMA, Drug development, Bone pain, Gaucher's disease, FACIT, Disease, Liver, Gene, Society, Standard of care, Annual general meeting, Pharmaceutical industry

LONDON, May 09, 2024 (GLOBE NEWSWIRE) --  Freeline Therapeutics today announced new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, showing substantial reductions in glucosylsphinogsine (lyso-Gb1), one of the best predictors of clinical response, in patients with persistently high levels despite years of treatment with currently approved therapies, as well as early signs of clinical improvements in bone marrow burden and fatigue. FLT201 continues to demonstrate a favorable safety and tolerability profile. These data are being showcased in a late-breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, Maryland.

Key Points: 
  • These data are being showcased in a late-breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, Maryland.
  • Reductions in lyso-Gb1 levels in the blood are highly correlated with substrate reduction in disease-affected tissues and positive clinical outcomes in Gaucher disease.
  • Currently approved treatments have made a significant difference for people with Gaucher disease, but there is not an existing cure.
  • Both the late-breaking oral presentation and the poster presentation are now available on the News & Events section of Freeline’s website.

Tragic loss of CN Rail worker mourned by United Steelworkers union

Retrieved on: 
木曜日, 4月 25, 2024
Incident response team, Safety, USW, Health, ERT, Friends, Injury, Family, Canadian National Railway, United Steelworkers

BURNABY, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- The United Steelworkers union (USW) announces with heavy hearts the tragic passing of 36-year old Juver Balmores, two days ago on April 23.

Key Points: 
  • BURNABY, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- The United Steelworkers union (USW) announces with heavy hearts the tragic passing of 36-year old Juver Balmores, two days ago on April 23.
  • Balmores, a dedicated worker at CN Rail and member of USW Local 2004, was involved in a fatal head-on collision near Clearwater, B.C., leaving behind a loving wife and three young children.
  • Another USW member was hospitalized due to injuries, while one occupant in a semi-truck passed away and another sustained injuries.
  • The union’s Emergency Response Team (ERT) is working with USW Local 2004, CN Rail and local authorities as they investigate the circumstances surrounding this tragic incident.

Radware Secures DNS Infrastructures With New AI-Powered, Rule-Free DDoS Protection

Retrieved on: 
水曜日, 4月 17, 2024
Knowledge, Flood, Denial-of-service attack, DNS, ERT, Gigaom, Forrester Research, Quadrant, Government, DNS Flood, Anomaly, Algorithm, Organization, Gartner, Cryptocurrency

For DNS service providers or companies that host their own DNS services, this can significantly shorten time to resolution and reduce total cost of ownership when countering even the most sophisticated DNS DDoS attack campaigns.

Key Points: 
  • For DNS service providers or companies that host their own DNS services, this can significantly shorten time to resolution and reduce total cost of ownership when countering even the most sophisticated DNS DDoS attack campaigns.
  • “There is now DNS DDoS protection available that no longer requires human intervention to handle the attack life cycle,” said Gabi Malka, Radware’s chief operating officer.
  • To ensure networks and services remain accessible and resilient, Radware’s new DNS DDoS protection offers:
    Radware's solution accurately identifies and mitigates the most sophisticated known and zero-day DNS DDoS threats as well as multi-vector attacks.
  • Radware’s DNS DDoS Protection is provided as a fully managed service and is backed by real-time support from seasoned security experts on Radware’s Emergency Response Team (ERT).

Verizon stands ready to respond during severe weather season and beyond

Retrieved on: 
水曜日, 4月 17, 2024
Core, Emergency, Weather, News, Safety, VZ, ERT, DIRT, Checklist, Insurance, Wildfire, Tornado, Military personnel, Smartphone, Senior, Government, Tablet, American Red Cross, Electric battery

Verizon stands ready to respond to any event as a result of year-round preparations including emergency drill exercises, network infrastructure enhancements and resource staging for rapid response.

Key Points: 
  • Verizon stands ready to respond to any event as a result of year-round preparations including emergency drill exercises, network infrastructure enhancements and resource staging for rapid response.
  • Additionally, Verizon boasts an industry leading 200 satellite-based portable network assets, providing crucial connectivity in scenarios where fiber connections are compromised.
  • The Verizon Response Team includes:
    Verizon’s Major Emergency Response Incident Team (MERIT), a specialized team of hazardous material-certified Verizon technicians and engineers.
  • Headquartered in New York City and with a presence around the world, Verizon generated revenues of $134.0 billion in 2023.

Chiesi Global Rare Diseases Announces Publication of Results from Fabry Disease Patient Survey

Retrieved on: 
水曜日, 4月 24, 2024
Pain, Enzyme replacement therapy, Hearing loss, Fabry disease, ERT, Genetics, Disease, LGC, Patient, Fatigue, Perception, Quality of life, Pharmaceutical industry

BOSTON, April 24, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.

Key Points: 
  • - Real-world evidence provides valuable insights about the management and monitoring of patients with Fabry disease for healthcare providers, researchers, and industry partners -
    BOSTON, April 24, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.
  • "There continues to be a general lack of awareness and a limited appreciation of the numerous unique challenges that rare disease patients face every day, including those who are living with Fabry disease," said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
  • The results of this survey will help us partner with healthcare providers to improve the care of patients with Fabry disease by addressing their most relevant unmet needs."
  • "Our analysis highlights the gap between current standard-of-care in disease monitoring and patient perception of disease progression among patients with Fabry disease."

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 3月 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

Verizon partners with U.S. military in extreme training to prepare for natural disaster response

Retrieved on: 
木曜日, 2月 29, 2024
VZ, PATRIOT, Senior, Emergency, Air force, Core, RSS, ERT, Military personnel, Exercise, DIRT, Government, National Guard, MEMA, Category, Camp Shelby, Wi-Fi, Verizon Communications, Mississippi National Guard, The, Partnership

The Verizon Response Teams participating in the drills included:

Key Points: 
  • The Verizon Response Teams participating in the drills included:
    Verizon’s Major Emergency Response Incident Team (MERIT), a specialized team of hazardous material-certified Verizon technicians and engineers.
  • Verizon’s Dedicated Impact Response Team (DIRT), technicians and engineers with specialty training in mobile satellite asset deployment, basic generator repair, and cable/connector making.
  • Verizon Frontline Crisis Response Team dedicated to providing on-demand, emergency communication assistance during crisis situations to government agencies and emergency responders, on a 24/7 basis.
  • Headquartered in New York City and with a presence around the world, Verizon generated revenues of $134.0 billion in 2023.

ILUS Signs Letter of Intent to Acquire a British Manufacturer of Autonomous Vehicles While Completing its Next Phase of Restructuring for Anticipated Growth

Retrieved on: 
火曜日, 2月 20, 2024
RB, Acquisition, Majority, OTC, Mergers and acquisitions, Growth, ERT, Defense, Letter, Information, Probability, Negotiation, SAML, Water, Security (finance)

This and several additional factors have led to increased instability, placing heightened demand on the defense and security sectors leading to increased growth.

Key Points: 
  • This and several additional factors have led to increased instability, placing heightened demand on the defense and security sectors leading to increased growth.
  • “This acquisition and those in the pipeline are expected to add incredible value to the ILUS Group.
  • Furthermore, ILUS is in discussions with RB Capital regarding the consolidation of its existing promissory notes into one single promissory note.
  • I am currently in the USA with JP Backwell for the final stage of the business combination transaction with the NASDAQ company.

Medecision Appoints Mark Gee as Chief Revenue Officer to Spearhead Growth and Innovation

Retrieved on: 
月曜日, 2月 26, 2024
Aerial, Emerging market, Innovation system, Utah State University, Growth, ERT, ED, Lean manufacturing, Cigna, Health care, Ecosystem, Patient, UnitedHealth Group, Management

DALLAS and KING OF PRUSSIA, Pa., Feb. 26, 2024 /PRNewswire/ -- Medecision , the leading clinical data and analytics platform company, has announced the addition of Mark Gee to its team as Chief Revenue Officer (CRO).

Key Points: 
  • DALLAS and KING OF PRUSSIA, Pa., Feb. 26, 2024 /PRNewswire/ -- Medecision , the leading clinical data and analytics platform company, has announced the addition of Mark Gee to its team as Chief Revenue Officer (CRO).
  • Gee brings a wealth of experience in healthcare leadership, with a deep focus on value-based care strategies, and enterprise sales.
  • Before joining Medecision, Gee was Chief Growth Officer of Payer and Emerging Markets at WellSky , driving strategy for payer, life sciences, and channel partners.
  • Kenneth Young, President and CEO of Medecision, said, "We are delighted to welcome Mark Gee to our team.